Drug Trial Radar · NCT03959085
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
5,951
Planned (sponsor's estimate)
Start
Oct 31, 2019
Primary completion
Mar 31, 2032
Study completion Mar 31, 2032
Sponsor
- Lead sponsor
- Children's Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- May 22, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 365 days, up to 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab ozogamicin is a monoclonal antibody, which is a type of protein that can bind to certain targets on the surface of cells. Inotuzumab ozogamicin is a monoclonal antibody that is linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells by binding to the CD22 protein on the surface of the cancer cell and delivering calicheamicin inside the cells to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Blinatumomab is a specialized type of monoclonal antibody known as a bispecific T-cell engager (BiTE). It works by simultaneously binding to CD19 on cancer cells and CD3 on normal immune cells, bringing them together to destroy leukemia cells. Blinatumomab is a standard part of chemo-immunotherapy treatment for B-ALL. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin or blinatumomab. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemo-immunotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first phase of therapy: Induction. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-induction treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (consolidation, blinatumomab block 1, interim maintenance 1, blinatumomab block 2, delayed intensification, interim maintenance 2, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of consolidation or part of delayed intensification. Other aims of this study include evaluating 1) side effects of treatment using patient-reported outcomes and health-related quality of life, 2) the best ways to help patients adhere to oral chemotherapy regimens, 3) the relationship between levels of inotuzumab ozogamicin in the blood and side effects, 4) the impact of chemo-immunotherapy on the immune system and risk of infection, and 5) the impact of social determinants of health on outcomes. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Conditions
- B Acute Lymphoblastic Leukemia
- B Lymphoblastic Lymphoma
- Central Nervous System Leukemia
- Mixed Phenotype Acute Leukemia
- Testicular Leukemia
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
BlinatumomabBiological
Given IV
Bone Marrow AspirationProcedure
Undergo bone marrow aspiration
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy
Bone ScanProcedure
Undergo bone scan
Calaspargase PegolDrug
Given IV
Computed TomographyProcedure
Undergo CT
CyclophosphamideDrug
Given IV
CytarabineDrug
Given IV, IT, or SC
Daunorubicin HydrochlorideDrug
Given IV
DexamethasoneDrug
Given PO or IV
Doxorubicin HydrochlorideDrug
Given IV
Inotuzumab OzogamicinBiological
Given IV
Leucovorin CalciumDrug
Given PO or IV
Magnetic Resonance ImagingProcedure
Undergo MRI
MercaptopurineDrug
Given PO
MethotrexateDrug
Given IT or IV
PegaspargaseDrug
Given IV or IM
Positron Emission TomographyProcedure
Undergo PET
PrednisoloneDrug
Given PO or IV
PrednisoneDrug
Given PO or IV
Questionnaire AdministrationOther
Ancillary studies
Radiation TherapyRadiation
Undergo testicular radiation therapy
Radiation TherapyRadiation
Undergo cranial radiation therapy
ThioguanineDrug
Given PO
Vincristine SulfateDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Post-induction 5-year event-free survival (EFS)Time frame: From study entry to first event (induction failure, induction death, end of induction [EOI] minimal residual disease [MRD] ≥ 5%,EO consolidation [C] MRD ≥ 0.01%, relapse, second malignancy, remission death) or date of last contact, assessed up to 5 years
Locations
231 sites in 5 countries. Site status is shown where the registry gives one.
Children's Hospital of Alabama
Birmingham, Alabama · Recruiting
USA Health Strada Patient Care Center
Mobile, Alabama · Recruiting
Providence Alaska Medical Center
Anchorage, Alaska · Recruiting
Banner Children's at Desert
Mesa, Arizona · Recruiting
Phoenix Childrens Hospital
Phoenix, Arizona · Recruiting
Banner University Medical Center - Tucson
Tucson, Arizona · Recruiting
Arkansas Children's Hospital
Little Rock, Arkansas · Recruiting
Kaiser Permanente Downey Medical Center
Downey, California · Recruiting
City of Hope Comprehensive Cancer Center
Duarte, California · Recruiting
Loma Linda University Medical Center
Loma Linda, California · Recruiting
Miller Children's and Women's Hospital Long Beach
Long Beach, California · Recruiting
Children's Hospital Los Angeles
Los Angeles, California · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
Mattel Children's Hospital UCLA
Los Angeles, California · Suspended
Valley Children's Hospital
Madera, California · Recruiting
UCSF Benioff Children's Hospital Oakland
Oakland, California · Recruiting
Kaiser Permanente-Oakland
Oakland, California · Recruiting
Children's Hospital of Orange County
Orange, California · Recruiting
Lucile Packard Children's Hospital Stanford University
Palo Alto, California · Recruiting
Sutter Medical Center Sacramento
Sacramento, California · Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
Rady Children's Hospital - San Diego
San Diego, California · Recruiting
Naval Medical Center -San Diego
San Diego, California · Recruiting
UCSF Medical Center-Mission Bay
San Francisco, California · Recruiting
Santa Barbara Cottage Hospital
Santa Barbara, California · Recruiting
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California · Active not recruiting
Children's Hospital Colorado
Aurora, Colorado · Recruiting
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
Denver, Colorado · Recruiting
Connecticut Children's Medical Center
Hartford, Connecticut · Recruiting
Yale University
New Haven, Connecticut · Recruiting
Alfred I duPont Hospital for Children
Wilmington, Delaware · Recruiting
MedStar Georgetown University Hospital
Washington D.C., District of Columbia · Suspended
Children's National Medical Center
Washington D.C., District of Columbia · Recruiting
Broward Health Medical Center
Fort Lauderdale, Florida · Recruiting
Golisano Children's Hospital of Southwest Florida
Fort Myers, Florida · Recruiting
UF Health Cancer Institute - Gainesville
Gainesville, Florida · Recruiting
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood, Florida · Recruiting
Nemours Children's Clinic-Jacksonville
Jacksonville, Florida · Recruiting
Palms West Radiation Therapy
Loxahatchee Groves, Florida · Active not recruiting
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida · Recruiting
Showing 40 of 231 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.